Literature DB >> 30832964

Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.

John Brazier1, Roberta Ara2, Ismail Azzabi3, Jan Busschbach4, Hélène Chevrou-Séverac5, Bruce Crawford6, Luciane Cruz7, John Karnon8, Andrew Lloyd9, Suzy Paisley2, A Simon Pickard10.   

Abstract

Cost-effectiveness models that present results in terms of cost per quality-adjusted life-year for health technologies are used to inform policy decisions in many parts of the world. Health state utilities (HSUs) are required to calculate the quality-adjusted life-years. Even when clinical studies assessing the effectiveness of health technologies collect data on HSUs to populate a cost-effectiveness model, which rarely happens, analysts typically need to identify at least some additional HSUs from alternative sources. When possible, HSUs are identified by a systematic review of the literature, but, again, this rarely happens. In 2014, ISPOR established a Good Practices for Outcome Research Task Force to address the use of HSUs in cost-effectiveness models. This task force report provides recommendations for researchers who identify, review, and synthesize HSUs for use in cost-effectiveness models; analysts who use the results in models; and reviewers who critically appraise the suitability and validity of the HSUs selected for use in models. The associated Minimum Reporting Standards of Systematic Review of Utilities for Cost-Effectiveness checklist created by the task force provides criteria to judge the appropriateness of the HSUs selected for use in cost-effectiveness models and is suitable for use in different international settings.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Keywords:  cost effectiveness; economic evaluation; health state utility; preference-based; quality of life; systematic reviews; utilities

Mesh:

Year:  2019        PMID: 30832964     DOI: 10.1016/j.jval.2019.01.004

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  36 in total

1.  Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses.

Authors:  Nathaniel Hendrix; David D Kim; Krishna S Patel; Beth Devine
Journal:  Med Decis Making       Date:  2021-01-15       Impact factor: 2.583

Review 2.  Road to comprehensive estimation of antimicrobial resistance (AMR) disease burden in Japan.

Authors:  Shinya Tsuzuki; Nobuaki Matsunaga; Norio Ohmagari
Journal:  Glob Health Med       Date:  2020-06-30

3.  Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists.

Authors:  Michael J Zoratti; A Simon Pickard; Peep F M Stalmeier; Daniel Ollendorf; Andrew Lloyd; Kelvin K W Chan; Don Husereau; John E Brazier; Murray Krahn; Mitchell Levine; Lehana Thabane; Feng Xie
Journal:  Eur J Health Econ       Date:  2021-04-11

Review 4.  Economic evaluation of CPAP therapy for obstructive sleep apnea: a scoping review and evidence map.

Authors:  Daniela V Pachito; Ângela M Bagattini; Luciano F Drager; Alan L Eckeli; Aline Rocha
Journal:  Sleep Breath       Date:  2021-03-31       Impact factor: 2.816

5.  Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.

Authors:  Boshen Jiao; Anirban Basu; Scott Ramsey; Joshua Roth; M A Bender; Dalyna Quach; Beth Devine
Journal:  Value Health       Date:  2021-09-04       Impact factor: 5.725

6.  GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-An overview in the context of health decision-making.

Authors:  Jan L Brozek; Carlos Canelo-Aybar; Elie A Akl; James M Bowen; John Bucher; Weihsueh A Chiu; Mark Cronin; Benjamin Djulbegovic; Maicon Falavigna; Gordon H Guyatt; Ami A Gordon; Michele Hilton Boon; Raymond C W Hutubessy; Manuela A Joore; Vittal Katikireddi; Judy LaKind; Miranda Langendam; Veena Manja; Kristen Magnuson; Alexander G Mathioudakis; Joerg Meerpohl; Dominik Mertz; Roman Mezencev; Rebecca Morgan; Gian Paolo Morgano; Reem Mustafa; Martin O'Flaherty; Grace Patlewicz; John J Riva; Margarita Posso; Andrew Rooney; Paul M Schlosser; Lisa Schwartz; Ian Shemilt; Jean-Eric Tarride; Kristina A Thayer; Katya Tsaioun; Luke Vale; John Wambaugh; Jessica Wignall; Ashley Williams; Feng Xie; Yuan Zhang; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2020-09-24       Impact factor: 6.437

7.  To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-12-10

8.  Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.

Authors:  Ting Zhou; Zhiyuan Chen; Hongchao Li; Feng Xie
Journal:  Med Decis Making       Date:  2021-04-03       Impact factor: 2.583

9.  Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review.

Authors:  Ting Zhou; Haijing Guan; Luying Wang; Yao Zhang; Mingjun Rui; Aixia Ma
Journal:  Front Public Health       Date:  2021-06-29

Review 10.  The impact of acute pneumococcal disease on health state utility values: a systematic review.

Authors:  Ryan O'Reilly; Sayako Yokoyama; Justin Boyle; Jeffrey C Kwong; Allison McGeer; Teresa To; Beate Sander
Journal:  Qual Life Res       Date:  2021-07-17       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.